Company intelligence / Profile preview

HypoPet

Zürich, Zürich, Switzerland

Ownership: Private
Development stage: Other

Overview

HypoPet developed HypoCat (Fel-CuMV), a conjugate vaccine for cats targeting Fel d 1, demonstrating reduced allergen levels in cat saliva and significant symptom relief for allergic cat owners in clinical studies; no major safety concerns reported

Therapeutic areas: Immunology
Modalities: VaccineConjugate vaccineVirus-like particle
Industry: Veterinary

Partnerships

Boehringer Ingelheim (parent, major partnership post-acquisition)

Beyond the preview

Go deeper on HypoPet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HypoPet.

Explore the full profile